Dr. Ryan J. Sullivan on Frontline Immunotherapy Sequencing in Melanoma

June 12, 2019
Ryan J. Sullivan, MD

Cancer Network spoke with Ryan J. Sullivan, MD, of Massachusetts General Hospital, about the debate between immunotherapy sequencing vs targeted therapy for melanoma.

Cancer Network spoke with Ryan J. Sullivan, MD, medical oncologist at Massachusetts General Hospital, about why immunotherapy sequencing rather than immunotherapy targeted therapy should be the frontline treatment for melanoma.

Related Content:

ASCO Annual Meeting: MelanomaMelanomaSkin Cancer
Chronic IRAEs With Adjuvant Anti–PD-1 Therapy More Common Than Previously Understood for Resected Melanoma
Phase 1/2 trial of Darovasertib With or Without Binimetinib Is Feasible, Safe for Metastatic Uveal Melanoma
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma